Company U.S. Stem Cell, Inc. Other OTC
Equities
USRM
US90350U1007
Biotechnology & Medical Research
Business Summary
Sales per Business
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Autologous Cell Therapies
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -59.13% |
Sales per region
USD in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -59.13% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Miguel Tomás
CEO | Chief Executive Officer | 58 | 31/12/02 |
Mark Borman
CHM | Chairman | 69 | 30/04/09 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Greg Knutson
BRD | Director/Board Member | 72 | 04/03/17 |
Director/Board Member | 100 | 31/05/03 | |
Mark Borman
CHM | Chairman | 69 | 30/04/09 |
Miguel Tomás
CEO | Chief Executive Officer | 58 | 31/12/02 |
Sheldon Anderson
BRD | Director/Board Member | 73 | 27/08/13 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 641,507,317 | 571,247,298 ( 89.05 %) | 0 | 89.05 % |
Company contact information
U.S. Stem Cell, Inc.
1560 Sawgrass Corporate Parkway 4th floor
33323-6217, Sunrise
+954 835 1500
http://www.us-stemcell.comSector
1st Jan change | Capi. | |
---|---|---|
+8.92% | 114B | |
+10.48% | 104B | |
-1.83% | 22.57B | |
-6.45% | 22.5B | |
-10.39% | 17.95B | |
-42.36% | 16.48B | |
-14.45% | 15.82B | |
+3.76% | 13.55B | |
+28.94% | 10.99B |